Adrenal Venous Sampling by Using Gadopentetate Dimeglumine in Patients with Contraindications for Iodinated Contrast Agents by Mitsuba, Naoya et al.
広島大学学術情報リポジトリ
Hiroshima University Institutional Repository
Title Adrenal Venous Sampling by Using Gadopentetate Dimegluminein Patients with Contraindications for Iodinated Contrast
Agents
Auther(s) Mitsuba, Naoya; Kurisu, Satoshi; Kato, Yasuko; Ishibashi,Ken; Fujii, Yuichi; Dohi, Yoshihiro; Nishioka, Kenji;
Kihara, Yasuki
Citation International journal of cardiology , 157 (2) : E23 - E25
Issue Date 2012
DOI 10.1016/j.ijcard.2011.09.022
Self DOI
URL http://ir.lib.hiroshima-u.ac.jp/00034796
Right (c) 2012 Elsevier Ireland Ltd. All rights reserved.
Relation
 1
Adrenal Venous Sampling by Using Gadopentetate Dimeglumine in Patients 
with Contraindications for Iodinated Contrast Agents 
Naoya Mitsuba, MD, Satoshi Kurisu, MD, PhD, Yasuko Kato, MD,  
Ken Ishibashi, MD, Yuichi Fujii, MD, PhD, Yoshihiro Dohi, MD, PhD,  
Kenji Nishioka, MD, PhD, Yasuki Kihara, MD, PhD 
 
Department of Cardiovascular Medicine, Hiroshima University Graduate 
School of Biomedical Sciences, Hiroshima, Japan 
 
Short title: Adrenal venous sampling by using gadolinium 
No grant 
Correspondence to:  
Satoshi Kurisu, MD 
1-2-3, Kasumi-cho, Minami-ku, 
Hiroshima, 734-8551, Japan 
Phone:+81-82-257-5540 
Fax:+81-82-257-1569 
E-mail: skurisu@nifty.com 
 
 
Fugure : 2 
Word counts : 987 
 
 2
Primary aldosteronism, which is characterized by hypertension, 
hypokalemia, decreased plasma renin activity (PRA) and increased 
aldosterone secretion, can be caused by both unilateral and bilateral adrenal 
lesions [1-3]. It is important to distinguish unilateral lesion from bilateral 
lesion because unilateral lesion is a curable form of secondary hypertension. 
The most reliable examination remains adrenal venous sampling guided by 
adrenal venography [4]. Iodinated contrast agents are routinely used in 
angiography. Anaphylactoid reaction to iodinated contrast agents is a rare, 
but life-threatening complication of angiography [5,6]. The use of gadolinium 
contrast agents of visceral, peripheral, carotid or coronary arteries has been 
recently reported in patients with contraindications for iodinated contrast 
agents or renal insufficiency [7-10]. In this report, we describe 2 cases of 
primary aldosteronism as well as contraindications for iodinated contrast 
agents, in which gadopentetate dimeglumine, gadolinium chelated by DTPA, 
was used as an alternative contrast agent for adrenal venography. 
 
A 63-year-old woman presenting with hypertension was admitted to our 
hospital. She had a history of anaphylactoid reaction to iodinated contrast 
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agents. The laboratory data were as follows: creatinine, 0.57 mg/dl; PRA, 0.8 
ng/ml/hr; plasma aldosterone concentration (PAC), 31.9 ng/dl; PAC to PRA 
ratio, 39.9. Confirmatory tests including captopril challenge test and 
furosemide plus upright test were positive. She was diagnosed as having 
primary aldosteronism. Plain computed tomography showed no adrenal 
tumor. She requested adrenal venous sampling by using gadolinium after 
explaining its risks and benefits. After written informed consent was 
obtained, adrenal venous sampling was performed through the right femoral 
vein. A 5-French catheter was positioned with its tip in the right or left 
adrenal vein. Gadopentetate dimeglumine was diluted 1:1 with sodium 
chloride before application. Gadopentetate dimeglumine was used for test 
injection to confirm catheter position, and anterior and lateral views of 
adrenal venography were obtained with acceptable quality by using this 
agent (Figure 1). Adrenal venous sampling was subsequently performed 
after adrenocorticotropic hormone (ACTH) stimulation. The total volume of 
gadopentetate dimeglumine was 12 ml. No adverse effects occurred during 
and after the procedure. She was diagnosed as having bilateral adrenal 
hypersecretion, and treated with eplerenone.  
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A 64-year-old woman presenting with hypertension was admitted to our 
hospital. The laboratory data were as follows: creatinine 0.52 mg/dl; PRA, 0.4 
ng/ml/hr; PAC, 11.7 ng/dl; PAC to PRA ratio 29.3. Confirmatory tests 
including captopril challenge test and furosemide plus upright test were 
positive. She was diagnosed as having primary aldosteronism. The 
abdominal computed tomography showed a mass of 15 mm in the left 
adrenal which was poorly enhanced after contrast enhancement. After the 
contrast-enhanced computed tomography examination, she complained of 
itching and dyspnea, which required a treatment with oxygen and infusion. 
The timing of these symptoms suggested an anaphylactoid reaction to the 
iodinated contrast agents. She requested adrenal venous sampling by using 
gadolinium after explaining its risks and benefits. After written informed 
consent was obtained, adrenal venous sampling was performed through the 
right femoral vein. A 5-French catheter was positioned with its tip in the 
right or left adrenal vein. Gadopentetate dimeglumine was diluted 1:1 with 
sodium chloride before application. Gadopentetate dimeglumine was used for 
test injection to confirm catheter position, and anterior and lateral views of 
adrenal venography were obtained with acceptable quality by using this 
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agent (Figure 2). Adrenal venous sampling was subsequently performed 
after ACTH stimulation. The total volume of gadopentetate dimeglumine 
was 9 ml. No adverse effects occurred during and after the procedure. She 
was diagnosed as having bilateral adrenal hypersecretion, and treated with 
eplerenone. 
 
Enhanced computed tomography is useful in planning adrenal venous 
sampling by demonstrating the anatomy and positions of the adrenal veins. 
However, patients with contraindications for iodinated contrast agents 
receive limited benefit from computed tomography because of no enhanced 
imaging. It is important to recognize the anatomy of adrenal veins by 
venography for obtaining good samples, and adrenal venous sampling should 
be performed by experienced operators [3,4].  
Major adverse effects of iodinated contrast agents are rare with the 
widespread use of non-ionic contrast agents [5,6]. However, anaphylactoid 
reaction to the iodinated contrast agents is still a major complication of 
angiography. Alternative methods that permit invasive imaging of adrenal 
veins are required in patients with contraindications to iodinated contrast 
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agents. One potential method for these conditions is to use corticosteroid for 
preventing anaphylactoid reaction to iodinated contrast agents before 
angiography [11]. However, there has been no clinical data assessing how 
much pretreatment with corticosteroid affect the results of adrenal venous 
sampling. We did not choice this method to obtain as reliable results as 
possible. The other potential method is to use gadolinium as an alternative 
contrast agent. Nelson et al reported that adverse reactions occurred in 2.4% 
of patients receiving this agent for magnetic resonance imaging. They also 
reported that patients with previous reactions to iodinated contrast agent 
had an adverse reaction rate of 6.3% [12]. Kalsch et al used gadolinium for 
coronary angiography in 19 patients with contraindications to iodinated 
contrast agents, and reported that 21% of the patients suffered complications 
due to gadolinium application such as malignant arrhythmias or 
hemodynamic decompensation [10]. These complications might result from 
non-physiological osmolality rather than gadolinium itself. In patients with 
renal insufficiency, nephrogenic systemic fibrosis has been reported to be a 
rare, but life-threatening complication associated with the use of gadolinium 
[13].  
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There have been few reports concerning the use of gadolinium for 
venography. However, we used gadopentetate dimeglumine for adrenal 
venography after assessing its risk and benefit in our cases of 
contraindications for iodinated contrast agents and normal renal function. 
Consequently, adrenal venograms were obtained with reduced, but 
acceptable quality. No adverse reaction occurred. The use of gadolinium is 
associated with an increased expense. However, only a little amount of 
gadolinium is required when adrenal venous sampling is performed by 
experienced operators. 
In conclusion, gadopentetate dimeglumine may be a suitable alternative 
contrast agent for adrenal venography in patients with contraindications for 
iodinated contrast agents. Our findings require further confirmation by 
larger patient numbers. 
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FIGURE LEGEND 
Figure 1 Right and left adrenal venograms in case 1 by using gadopentetate 
dimeglumine. These were obtained with reduced, but acceptable quality. 
 
Figure 2 Right and left adrenal venograms in case 2 by using gadopentetate 
dimeglumine. These were obtained with reduced, but acceptable quality. 
 
 


